<DOC>
	<DOCNO>NCT00784420</DOCNO>
	<brief_summary>The purpose study estimate effect steady state raltegravir steady state pharmacokinetics UK-453,061 steady state UK-453,061 steady state pharmacokinetics raltegravir .</brief_summary>
	<brief_title>Drug Interaction Study Between Raltegravir And UK-453,061</brief_title>
	<detailed_description />
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Healthy male and/or female subject age 18 55 year , inclusive ; Body Mass Index ( BMI ) 18 30 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . A BMI low limit 17.5 kg/m2 may round 18.0 kg/m2 ; BMI upper limit 30.5 kg/m2 may round 30.0 kg/m2 acceptable inclusion . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ; Treatment investigational drug within 30 day 5 halflives ( whichever longer ) precede first dose study medication ; Use tobacco nicotinecontaining product excess equivalent 5 cigarette per day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>Drug Interaction , Pharmacokinetics</keyword>
</DOC>